Press release
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the fourth quarter of 2022.\n\n“We’re building momentum for our commercial business with continued double-digit revenue growth for our treprostinil products,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “In addition, we are marching toward pivotal clinical data for Tyvaso in idiopathic pulmonary fibrosis and ralinepag in pulmonary arterial hypertension.”\n\n“We are tremendously proud of reaching our goal of doubling the number of patients on Tyvaso therapy since the Tyvaso PH-ILD approval in early 2021,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “We’re now focused on continued commercial uptake of Tyvaso and Tyvaso DPI in both PAH and PH-ILD to support our long-term goal of doubling our revenue to a $4 billion run rate by the end of 2025.”\n\nFourth Quarter and Full Year 2022 Financial Results\n\nKey financial highlights include (in millions, except per share data):\n\n\n\n \n\n\n\nThree Months Ended\nDecember 31,\n\n\n\n \n\n\n\nYear Ended\nDecember 31,\n\n\n\n\n\n \n\n\n\n2022\n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n2022\n\n\n\n \n\n\n\n2021\n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nTotal revenues\n\n\n\n$\n\n\n\n491.5\n\n\n\n\n \n\n\n\n$\n\n\n\n415.2\n\n\n\n\n \n\n\n\n$\n\n\n\n1,936.3\n\n\n\n\n \n\n\n\n$\n\n\n\n1,685.5\n\n\n\n\n\n\nNet income\n\n\n\n$\n\n\n\n132.1\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n112.2\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n727.3\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n475.8\n\n\n\n \n\n\n\n\n\nNet income, per basic share\n\n\n\n$\n\n\n\n2.88\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n2.49\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n15.98\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n10.60\n\n\n\n \n\n\n\n\n\nNet income, per diluted share\n\n\n\n$\n\n\n\n2.67\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n2.35\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n15.00\n\n\n\n \n\n\n\n \n\n\n\n$\n\n\n\n10.06\n\n\n\n \n\n\n\n\nRevenues\n\nThe t...